Authors
Latest:
Eisai Rises in the WestTne product still in naming, a potential Big Pharma partner, and a foothold field force in North America-those were the works in progress when we toured Eisai Co.'s headquarters and operations in Japan a few years ago.
Latest:
New Gains for PainThe global pain market will reach nearly $29.8 billion in 2008, of which $21.8 billion will come from the United States.
Latest:
War Games: Win Your Brand with ActionStan Bernard outlines the seven ways for pharmas to ensure successful execution of action steps following brand ‘war games’.
Latest:
Path of Uncertainty: Pharm Exec’s 2017 Industry ForecastThe populist-driven shifts trumpeted from the US to the EU leaves plenty of question marks when trying to size up the trajectory of the global pharma industry. One certainty, however, will be change.
Latest:
Pharm Exec's 2018 Pipeline ReportAnalysis shows that persistence is paying off for drug developers, driven by the rise of CAR-T and other gene therapy, newly discovered cancer targets, better patient identification methods-and the realization that failures have their place in shaping the pipeline of tomorrow.
Latest:
New Patent-Defense Path for PharmaInter Partes Review can potentially offer a more economical and streamlined litigation strategy for pharma and biotech players, writes David Dalke.
Latest:
Planning for the Future of SerializationCompliance with the new traceability requirements necessitates an understanding of how and when to begin implementing changes in an ever-evolving industry.
Latest:
Executive Coaching: Transforming Big Pharma from WithinDefining the critical coaching steps necessary for top managers to realize their potential in an industry undergoing significant restructuring of human and financial capital.
Latest:
Beyond 2020: Building Strategic Coherence in the New Health EconomyPositioning for success in biopharma requires a self-critical analysis of the risk and rewards among four categories of value differentiation. The key question: How do you define yourself against the competition?
Latest:
The Human Microbiome—Our Body's Secret WeaponNew research on the role of microbes in fighting disease is transforming the way medicine views bacteria, writes Lee Jones.
Latest:
Ireland’s Role in the European Union’s Evolving Pharmaceutical SectorRory Mullen outlines Ireland’s importance to multinational pharma in the changing EU landscape.
Latest:
The Fruits of Comparative EffectivenessNew CER tools grant payers the evidence they need to control drug costs
Latest:
Plant ManagementWe ask three managers building Greenfield plants to rationalize and defend their decisions
Latest:
FDA Feels Pinch of House Funding CutsThe House Appropriations Committee released the fiscal year 2013 Agriculture Appropriations bill, which, sets proposed spending levels for FDA as well as for other programs.
Latest:
AI-based Social Listening as Aid to PharmacovigilanceHow artificial intelligence can help pharma filter out the online noise when monitoring for safety signals on the web.
Latest:
Country Report: The Czech RepublicAlthough still tightly regulated, healthcare industry stakeholders-buoyed by regulatory reforms aimed at increasing patient access to innovative new therapies-are cautiously optimistic that the Czech Republic will further close the gap with Western Europe.
Latest:
The Fruits of Comparative EffectivenessNew CER tools grant payers the evidence they need to control drug costs
